Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... it will also be adding two new doses, as competition in the space continues to heat ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss ...

The third risk to consider here would be in terms of competition in the ... and starts to eat away at its market share. That's because reduced sales of Zepbound and Mounjaro, would force this ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.